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Abstract
Background: Bordetella holmesii is a human pathogen closely related to B. pertussis, the etiological
agent of whooping cough. It is able to cause disease in immunocompromised patients, but also
whooping cough-like symptoms in otherwise healthy individuals. However, virtually nothing was
known so far about the underlying virulence mechanisms and previous attempts to identify
virulence factors related to those of B. pertussis were not successful.
Results: By use of a PCR approach we were able to identify a B. holmesii gene encoding a protein
with significant sequence similarities to the filamentous hemagglutinin (FHA) of B. avium and to a
lesser extent to the FHA proteins of B. pertussis, B. parapertussis, and B. bronchiseptica. For these
human and animal pathogens FHA is a crucial virulence factor required for successful colonization
of the host. Interestingly, the B. holmesii protein shows a relatively high overall sequence similarity
with the B. avium protein, while sequence conservation with the FHA proteins of the human and
mammalian pathogens is quite limited and is most prominent in signal sequences required for their
export to the cell surface. In the other Bordetellae expression of the fhaB gene encoding FHA was
shown to be regulated by the master regulator of virulence, the BvgAS two-component system.
Recently, we identified orthologs of BvgAS in B. holmesii, and here we show that this system also
contributes to regulation of fhaB expression in B. holmesii. Accordingly, the purified BvgA response
regulator of B. holmesii was shown to bind specifically in the upstream region of the fhaB promoter
in vitro in a manner similar to that previously described for the BvgA protein of B. pertussis.
Moreover, by deletion analysis of the fhaB promoter region we show that the BvgA binding sites
are relevant for in vivo transcription from this promoter in B. holmesii.
Conclusion: The data reported here show that B. holmesii is endowed with a factor highly related
to filamentous hemagglutinin (FHA), a prominent virulence factor of the well characterized
pathogenic Bordetellae. We show that like in the other Bordetellae the virulence regulatory BvgAS
system is also involved in the regulation of fhaB expression in B. holmesii. Taken together these data
indicate that in contrast to previous notions B. holmesii may in fact make use of virulence
mechanisms related to those described for the other Bordetellae.
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Background
The genus Bordetella  currently comprises nine species,
most of which were found to be associated with host
organisms [1,2]. Medically the most important species is
B. pertussis, the etiological agent of whooping cough for
which humans are the only known host. B. parapertussis
causes milder forms of whooping cough-like disease in
humans. B. bronchiseptica is known to cause respiratory
disease in various mammalian species, but only rarely in
humans [2]. These "classical" Bordetella species are closely
related and the recent determination of their genome
sequences confirmed previous suggestions that B. pertussis
and  B. parapertussis are independent descendents of B.
bronchiseptica-like ancestors which during specialization
to a single host have sustained a significant erosion of
their genetic material [3]. In agreement with their close
relationship these organisms produce highly related viru-
lence factors such as several toxins and colonization fac-
tors [2].
Among these virulence factors the filamentous hemagglu-
tinin FHA is of particular relevance for pathogenesis. It is
an important adhesin and it is required for tracheal colo-
nization in animal models [4]. FHA is a huge protein syn-
thesized as a precursor of 367 kDa which is processed to a
mature protein of about 220 kDa by extensive N-terminal
and C-terminal modifications involving possibly the Lep
signal peptidase and the subtilisin-like autotransporter
protein SphB1 [5,6]. FHA is exported to the cell surface
and/or secreted via a two-partner export mechanism
requiring the FhaC protein located in the outer membrane
of the bacteria [7,8]. It has several distinct binding
domains involved in adhesion to different substrates. The
carbohydrate recognition domain (CRD) probably ena-
bles the bacteria to attach to ciliated respiratory epithelial
cells and to macrophages [9]. FHA exhibits lectin-like
activity for heparin and dextran sulphate possibly
involved in the interaction with nonciliated epithelial
cells which also contributes to FHA-mediated hemaggluti-
nation [10]. Furthermore, there is an Arg-Gly-Asp (RGD)
motif which enables FHA to adhere to human monocytes/
macrophages via the leukocyte integrin complement
receptor 3 (CR3, alpha M beta 2, CD11b/CD18) [11]. The
FHA proteins of the "classical" species are highly related,
but not entirely functionally exchangeable. Recently, by
use of a B. bronchiseptica strain expressing the B. pertussis
FHA protein it was found that the heterologous protein
could mediate adherence to various epithelial and macro-
phage cell lines in vitro. In contrast, in rat infection models
significant differences in the host-pathogen interaction
were noted for the mutant B. bronchiseptica strain suggest-
ing significantly different activities of the closely related
FHA proteins of the classical species and a role of FHA for
host adaptation [12]. Two other proteins, FhaL and FhaS,
with significant sequence similarity to FHA are present in
the members of the B. bronchiseptica cluster, but their func-
tional relevance in virulence is not yet clear [3]. As in case
of most other virulence factors, the expression of the fhaB
locus is controlled by the BvgAS two-component system
which is responsive to environmental stimuli such as tem-
perature or compounds such as MgSO4 or nicotinic acid
[13,14]. The architecture of the fhaB promoter and its acti-
vation mechanism by the BvgAS system has been investi-
gated in much detail [15,16]. Finally, FHA is a protective
antigen and it is included in acellular pertussis vaccines
[2].
More recently, additional species were included in the
genus Bordetella. In 1984, B avium, a respiratory pathogen
of birds, was first described. The genome sequence of B.
avium was recently established and revealed the presence
of several factors orthologous to those of the "classical"
Bordetellae including FHA and the BvgAS two-component
system [17,18]. Among other "novel" Bordetella species
occasionally isolated from patients with underlying dis-
ease such as B. hinzii and B. trematum, B. holmesii has
gained most attention in the past years, since its 16S rDNA
sequence suggested this organism to be most closely
related to B. pertussis [2,19]. Moreover, B. holmesii is
known to contain several copies of the insertion elements
IS481 and IS1001, otherwise found only in B. pertussis and
B. parapertussis, respectively [20,21]. In addition to its iso-
lation from immunocompromised patients [22-24], B.
holmesii was found to be able to cause whooping-cough
like symptoms in otherwise healthy persons [25,26]. Very
little was known about the virulence properties of this
bacterium and attempts to identify virulence factors
related to those of B. pertussis failed. Recently, we suc-
ceeded to identify the BvgAS two-component system of B.
holmesii by PCR amplification with degenerate oligonucle-
otides [27]. Interestingly, in contrast to the close relation-
ship of the 16S rDNA sequences of B. holmesii and B.
pertussis, the B. holmesii BvgAS system was found to be
more closely related to the orthologous BvgAS system of
B. avium than to that of B. pertussis [27].
Based again on a PCR approach with degenerate oligonu-
cleotides we attempted to identify additional putative vir-
ulence factors of B. holmesii related to those of B. pertussis.
Here we describe the identification and initial characteri-
zation of an FHA orthologue of B. holmesii. We show that
the FHA protein of B. holmesii is more closely related to
that of B. avium than to the FHA proteins of the "classical"
Bordetellae. Furthermore, we show that similar to FHA of
all other species it is transcriptionally regulated by the
BvgAS two-component system suggesting similar viru-
lence strategies in the different Bordetella species.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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Results and Discussion
Identification and sequence analysis of the fhaB gene of B. 
holmesii
Based on short regions of highly conserved nucleotide
sequences of the 5'- and 3'-ends of the fhaB genes of B.
avium and B. pertussis oligonucleotide pairs Fha1F/Fha1R
and Fha2F/Fha2R were designed and used for PCR ampli-
fication with chromosomal DNA of B. holmesii. For both
primer combinations PCR products could be amplified.
The sequence analysis of the amplified DNA fragments
revealed significant similarity in particular in the deduced
amino acid sequence to the respective fhaB sequences of
the other Bordetellae. By PCR amplification using the
primer pair Fha1F/Fha1R, we found that all B. holmesii
strains tested (B. holmesii G7702, B. holmesii G8341, B.
holmesii ATCC51541 and B. holmesii No1) harbour ortho-
logues of this fhaB  gene (data not shown). Using a
genome walking strategy the DNA sequence of the fhaB
gene of strain B. holmesii G7702 was completed. The fhaB
coding region of B. holmesii starts with a GTG codon and
comprises 8,793 bp with a coding capacity for a 304 kDa
protein, which is smaller than FHA of B. pertussis (367
kDa) but larger than the respective protein of B. avium
(273 kDa). The genome organisation of the fhaB locus of
B. holmesii differs from that of the other Bordetella species.
In B. holmesii, upstream of the fhaB gene an open reading
frame (orfMP) is located with significant similarity to a
conserved integral membrane protein of B. bronchiseptica
(BB3004) and B. parapertussis (BPP3041) which is tran-
scribed divergently. Directly downstream of the fhaB gene
a copy of the insertion element IS1001 is located which is
known to occur in B. holmesii and in B. parapertussis. In
contrast, in the species belonging to the B. bronchiseptica
cluster the fhaB gene is arranged between the divergently
transcribed bvgAS locus and the fimbrial operon fimABCD
which precedes the fhaC  gene whose gene product is
involved in the export of FHA. In B. avium an ORF encod-
ing an ABC transporter is present upstream of fhaB, while
the downstream gene organization is similar to the B.
bronchiseptica cluster (Fig. 1) [3,17,18].
The overall similarity of the nucleotide sequence of the
fhaB gene of B. holmesii with those of B. avium and B. per-
tussis is low (between 50% and 52%) explaining the fail-
ure of previous attempts to detect an fhaB orthologue in
this species by Southern hybridization experiments (data
not shown). Even in those regions of the B. holmesii fhaB
gene (e.g. within the first 600 bp) in which the predicted
amino acid sequences of the FHA proteins are quite con-
served (see below), the nucleotide sequence similarity is
quite limited (59%). On the level of the deduced amino
acid sequences, the B. holmesii FHA protein shows an over-
Schematic view of the gene loci encoding fhaBin B. pertussis, B. avium and B. holmesii Figure 1
Schematic view of the gene loci encoding fhaBin B. pertussis, B. avium and B. holmesii. Relevant genes are repre-
sented as boxes. The arrows below the boxes show the transcriptional polarity of each gene. The open reading frame orfMP of 
B. holmesii encoding a putative membrane is not yet completely sequenced. The shaded regions (marked A to D) within the 
fhaB gene of B. holmesii indicate the degree of similarity of the deduced protein sequence with that of the FHA protein of B. 
avium. Region A comprises approximately amino acids 1–850, region B amino acids 950 to 1,640, region C amino acids 1,900 to 
2,600, and region D amino acids 2,830 to 2,930 of the B. holmesii FHA protein; these regions correspond to amino acids 1–820, 
840–1,540, 1,600–2310, and 2,520–2621 of the B. avium protein, respectively.
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all similarity of 55% to the FHA protein of B. avium (Fig.
1). The similarity to the FHA, FhaL and FhaS proteins of
the members of the B. bronchiseptica complex is less pro-
nounced, e.g. 39.2% to FHA of B. pertussis as calculated
using the EMBOSS pairwise alignment algorithms http://
www.ebi.ac.uk/emboss/align/ (Table 1). With a sequence
similarity of 37.3% the most similar protein outside of the
genus Bordetella is an adhesin-like protein from Yersinia
frederiksenii, an environmental bacterium that can also be
associated with a wide variety of host organisms [28]. This
analysis shows that FHA of B. holmesii is more similar to
the B. avium protein than to the related factors of the
mammalian pathogens, in line with previous observa-
tions that the BvgA, BvgS and RecA proteins of B. holmesii
and B. avium are more closely related to each other than
they are to those of the B. bronchiseptica complex [29,30].
This contrasts previous data obtained by comparison of
the 16S rDNA sequences, which placed B. holmesii as a
new species closer to B. pertussis than to B. avium. On the
other hand, recent evidence indicated that the gene
encoding the 16S RNA of B. holmesii may have been
acquired horizontally from B. pertussis [30].
For the Sec-dependent secretion across the cytoplasmic
membrane, the B. holmesii FHA protein has an extended
N-terminal signal sequence, which is very similar to that
of the B. pertussis protein. In B. pertussis, the signal
sequence is cleaved at an alanine at sequence position 71
probably by the Lep signal peptidase [6]. The B. holmesii
FHA protein has also an alanine residue at this position
suggesting its processing at this site after transport
through the cytoplasmic membrane. In addition, the N-
terminus of B. pertussis FHA harbours a domain about 250
amino acid residues in length which is essential for secre-
tion through the outer membrane according to the two-
partner secretion model, the so-called TPS domain [31].
The exact nature of the transport signal is not known so
far, but two sequence motifs (NPNL and NPNGI) are well
conserved among two-partner secreted proteins and at
least the NPNL motif plays a role in the secretion of B. per-
tussis FHA [32]. Both sequence motifs are also present in
the FHA protein of B. holmesii suggesting that it is also
exported via a two-partner secretion mechanism.
Similarities of the B. holmesii protein with domains of the
B. pertussis FHA protein possibly involved in adhesion
including the heparin binding (aa 442–862) and carbohy-
drate recognition domains (CRD) (aa 1141–1279) are
very limited and the elucidation of relevant binding activ-
ities must await the biochemical characterization of the B.
holmesii FHA protein. An intriguing feature of the FHA
protein of B. pertussis is the presence of an RGD motif (aa
1097–1099) enabling the protein to interact with integrin
receptors [2]. The B. holmesii protein does not contain an
RGD motif, instead at sequence position 742–744 it har-
bours a KGD motif (Fig. 2). In some cases, KGD motifs
may be involved in integrin binding [33,34], however,
ascribing such a function to the KGD motif of the B. hol-
mesii protein must await future experimental analysis.
Regulation of expression of the B. holmesii fhaB gene
Upstream of the fhaB gene a divergently transcribed gene
is present suggesting that the fhaB gene has a promoter of
its own. To analyse the regulatory region of the fhaB gene
(PfhaB) it was cloned upstream of a promoterless gfp gene
in the broad host range vector pMMB208 and the result-
ing plasmid was introduced into B. holmesii. By primer
extension analysis with a gfp-specific primer three tran-
scripts (P1 – P3) were identified initiating at sequence
positions -58 (P1), -71 (P2) and -88 (P3) with respect to
the translational start codon of the fhaB gene (Fig. 3). No
obvious -10 and -35 regions could be observed upstream
of any of these putative transcriptional start sites. To inves-
tigate whether, similar to the other Bordetellae, the BvgAS
system is involved in the control of fhaB  expression,
primer extension analysis was performed on RNA
extracted from a B. holmesii bvgAS mutant [27] harbouring
the plasmid-borne PfhaB-gfp fusion. Interestingly, the long-
est of the three transcripts (P3) was not detected in the
bvgAS mutant indicating that the synthesis of this tran-
script is controlled by the BvgAS system, while the other
transcripts are constitutively produced under our experi-
mental conditions (Fig. 3). Similarly, the fhaB gene of B.
pertussis is controlled by a BvgAS regulated promoter, but
some constitutive expression was noted [35].
Although the fhaB gene is transcribed in B. holmesii grown
at standard culture conditions, various attempts to detect
Table 1: Amino acid sequence similarity of the B. holmesii FHA protein and other FHA-like proteins of Bordetella species
FHA BP1) FhaL BP FhaS BP FHA BB FHA BA
FHA BH 39.2/28.12) 29.4/19.9 37.3/26.1 38.0/26.9 55.5/41.5
FHA BP 31.5/22.7 49.2/38.8 91.2/89.0 40.0/27.7
FhaL BP 30.7/23.1 29.6/21.1 29.2/19.4
FhaS BP 43.3/37.3 41.3/27.5
FHA BB 39.2/26.8
1) BP: B. pertussis; BB: B. bronchiseptica; BA: B. avium; BH: B. holmesii
2) Sequence similarity in %/Sequence identity in %BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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the B. holmesii FHA protein were not successful so far. The
B. holmesii strains used in this study grow very poorly in
liquid culture reaching a maximal OD600 of about 0,5. We
were unable to detect a protein with a molecular weight
corresponding to FHA in the culture supernatants neither
by SDS PAGE nor by immune blotting using a polyclonal
antiserum against the B. pertussis FHA protein. Similarly,
also in whole cell lysates of bacteria grown on BG agar
plates no FHA protein could be detected (data not
shown). It is therefore possible, that the translation effi-
ciency of the fhaB gene is low, which may be in line with
the fact that the open reading frame starts with a GTG
codon, or that the protein is processed to smaller frag-
ments than the related proteins of the other Bordetellae.
To further investigate the transcriptional regulation of the
fhaB gene by the BvgAS system we performed DNA bind-
ing experiments in vitro with purified recombinant BvgABH
of B. holmesii [27]. In fact, in band shift experiments bind-
ing of the phosphorylated but not of the unphosphor-
ylated BvgABH protein to the fhaB upstream region could
be detected (Fig. 4). Binding was specific since addition of
unspecific competitor DNA did not interfere with binding
of BvgABH-P even in the presence of a 1,000 fold excess of
competitor DNA (data not shown). To further character-
ize BvgA binding to the promoter region, DNase I foot-
print analysis with BvgABH of B. holmesii was performed.
Footprint experiments were carried out on a 312 bp DNA
segment ranging from nucleotide position +29 to -283 as
numbered with respect to the translational start site of the
fhaB gene. The addition of BvgABH-P to the reaction mix-
ture resulted in a large region protected from DNase I
digestion ranging from position -40 to -243 with respect
to the start codon of fhaB. Within the protected region the
appearance of a regular pattern of hypersensitive sites
every 10 to 11 nucleotides could be observed (Fig. 5), a
phenomenon which was noted previously in the case of
the promoter of the bvgAS operon of B. holmesii [27]. Sur-
prisingly, the protected area covers all three transcrip-
tional start sites mapped by primer extension analysis
and, accordingly, includes the corresponding core pro-
moter elements. It is not clear whether this observation
has in vivo relevance.
A search for putative BvgA binding sites within the fhaB
promoter region revealed the presence of four sequence
motifs termed BS1 to BS4, respectively, with similarities to
the well defined BvgA binding sites in B. pertussis (Fig. 6)
which are located within or close to the region protected
by BvgABH-P in the footprint experiments. BS2 and BS3
show high similarity to each other and consist of inverted
repeat heptanucleotide sequences centered at position -
117 and -65.5 relative to the start site of transcript P3. The
left and right half-site motifs of BS2 and BS3 match the
consensus half-site motif for binding of B. pertussis BvgA
(BvgABP) [15] in 4 and 5 (BS2) and 5 (BS3) out of seven
positions. BS1 is arranged as a direct heptanucleotide
repeat whose half-sites match the consensus in 5 and 6
positions, respectively, and is centered at position -161.
BS4 which consists of an inverted repeat centered at posi-
tion -47.5 shows the lowest similarity to the consensus
heptanucleotide BvgABP binding motif (4 and 3 matches
per half-site). The fhaB promoter of B. pertussis comprises
a heptanucleotide inverted repeat sequence with high
Schematic representation of the overall structureof FHA proteins of B. pertussis and B. holmesii Figure 2
Schematic representation of the overall structureof FHA proteins of B. pertussis and B. holmesii. Protein regions 
with known or presumable functional importance are represented by dark grey boxes. The arrow indicates the maturation site 
for proteolytic cleavage of the B. pertussis FHA by the SphB1 protease. Abbreviations: N, N terminus; C, C terminus; SP, signal 
peptide; TPS, two-partner secretion domain; HBD, heparin binding domain; RGD, arginine-glycine-aspartic acid motif; CRD, 
carbohydrate binding motif; KGD, lysine-glycine-aspartic acid motif. Numbers indicate amino acid positions within the FHA 
proteins.
B. pertussis FHA N
N
C
C B. holmesii FHA
SP  TPS
SP  TPS
HBD RGD
KGD
CRD
1-71 72-338
1-71 72-332
442-862 1097-1099
742-744
1141-1279 2165 3590
2931BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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affinity for BvgABP binding centered at position -88.5 rela-
tive to the transcriptional start, as well as two additional
low affinity binding sites centered at position -67.5 and
directly adjacent to the -35 region [14,15]. Cooperative
binding of BvgABP to the secondary binding sites which
show only limited similarity to the high-affinity inverted
repeat motif is required for full transcriptional activation
of the fhaB promoter of B. pertussis [15,35]. Remarkably,
the positions of the low-affinity BvgABP binding sites in
the fhaB promoter of B. pertussis and of BS3 and BS4 in the
upstream region of fhaB from B. holmesii are almost iden-
tical. However, while the high-affinity binding site in the
fhaB  promoter of B. pertussis is located immediately 5'
adjacent to the low-affinity sites, the centers of the
inverted repeat sequences BS2 and BS3 are located in a
distance of 51 bp. The most prominent sites showing
hypersensitivity to DNase I cleavage in footprint experi-
ments map to the region flanked by BS2 and BS3 (Fig. 5).
To investigate a functional role of these putative BvgA
binding site(s) we performed a deletion analysis of the
fhaB promoter region and carried out band shift assays
with progressively 5'- truncated DNA fragments lacking
BS1 to BS4. As shown in Fig. 7, BvgABH-P bound equally
well to DNA fragments comprising the four putative BvgA
binding sites BS1 to BS4 and to a DNA fragment lacking
BS1 suggesting a negligible role of BS1 for the activation
of the BvgA-P dependent promoter of fhaB. In agreement
with this assumption, BS1 was only partially protected by
BvgABH-P binding in DNase I footprint experiments (Fig.
6). When BvgABH-P was incubated with a DNA fragment
lacking both BS1 and BS2 still a distinct DNA-protein
complex was formed, however, binding was significantly
weaker since a much higher amount of BvgABH-P was
required to achieve a band shift. No significant binding of
BvgABH-P was detectable to DNA fragments containing
only BS4 or no BS box at all. These data suggest a func-
tional role of the highly similar BS2 and BS3 sites for
binding of BvgABH-P to the fhaB upstream region.
To test whether these in vitro data have also relevance in
vivo, DNA fragments containing various pieces of the fhaB
upstream region were cloned in a promoterless gfp expres-
Binding of BvgABH to the fhaB upstream region of B. holmesii Figure 4
Binding of BvgABH to the fhaB upstream region of B. 
holmesii. A radiolabelled 277 bp PCR fragment containing 
the fhaB upstream region of B. holmesii was incubated with 
150, 350, 500 and 650 ng of unphosphorylated (lanes 1–4) 
and in vitro phosphorylated (lanes 5–8) BvgABH, respectively. 
Lane 9 contains the radiolabelled DNA probe. The reaction 
mixtures were run on a non-denaturating 4% polyacrylamide 
gel. F, free DNA; C, DNA-protein complex.
Determination of transcriptional start sites of the gfp  reporter gene fused to the upstream region of fhaB of B. hol- mesii by primer extension analysis Figure 3
Determination of transcriptional start sites of the gfp 
reporter gene fused to the upstream region of fhaB 
of B. holmesii by primer extension analysis. Equal 
amounts of total RNA extracted from B. holmesii G7702 
(pMMB208-fhaP-gfp0) (lane 1) and B. holmesii G7702 bvgA 
(pMMB208-fhaP-gfp0) (lane 2) were hybridized with radiola-
belled oligonucleotide gfp.PE. The cDNAs corresponding to 
the transcripts P1 to P3 are indicated by arrows. A part of 
the fhaB promoter sequence is shown on the left. Transcrip-
tional start points are indicated by arrows. The sequencing 
reaction (lanes A, C, G and T) was performed using oligonu-
cleotide gfp.PE and plasmid pSK-fhaP-gfp0 as a template.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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Binding of the B. holmesii BvgABH protein to the fhaB upstream region of B. holmesii Figure 5
Binding of the B. holmesii BvgABH protein to the fhaB upstream region of B. holmesii. The footprint shows the 
entire region protected by BvgABH as indicated by the bar on the right side of the figure. DNase I footprint experiments were 
performed on a 312 bp BamHI-HindIII DNA fragment from plasmid pSK-FP labelled at its BamHI site containing the entire fhaB 
upstream sequence including all four putative binding sites (BS1–BS4). The 5'-labelled probe was incubated with 0.5, 1.0, 2.0, 
3.0, 4.0, 6.0 and 8.0 µg of in vitro phosphorylated BvgABH (lanes 4–10, respectively). No protein was added to the reaction mix-
ture loaded in lane 3. Lane 1 and 2 are G+A sequencing reactions on the DNA probe used as a size marker [42]. Numbers on 
the left indicate the distance from the translational start codon of the fhaB gene. The positions of the start sites of transcripts 
P1–P3 are indicated.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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Representation of the intergenic region between orfMP and fhaB of B. holmesii Figure 6
Representation of the intergenic region between orfMP and fhaB of B. holmesii. Partial amino acid sequences are 
shown below the respective coding DNA sequences. The GTG start codon of fhaB and the ATG start codon of the neighbour-
ing orfMP coding for a putative membrane protein are given in bold letters. The putative Shine/Dalgarno sequence of fhaB is 
shown in italics and underlined. Transcriptional start sites of the constitutively synthesized transcripts P1 and P2 and of the bvg-
dependent transcript P3 of fhaB are marked by arrows. The region protected from DNaseI digestion in footprint experiments 
with BvgABH-P is underlined. The sequence motifs BS1 to BS4 showing similarity to the BvgA consensus binding site in B. pertus-
sis promoters are indicated by horizontal arrows above and below the DNA sequence. Nucleotides which match the consen-
sus sequence are marked in bold letters.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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Characterization of putative BvgA binding sitesinside the fhaB upstream region of B. holmesii Figure 7
Characterization of putative BvgA binding sitesinside the fhaB upstream region of B. holmesii. (a) Schematic rep-
resentation of the fhaB upstream region containing the four putative BvgA binding sites BS1–BS4 and representation of the 
PCR amplified DNA probes I-V used for band shift experiments with the purified B. holmesii BvgABH protein. Numbers indicate 
the distance from the Bvg-dependent fhaB transcriptional start site (P3) taken as position +1. (b) Binding of the B. holmesii 
BvgABH protein to DNA probes I-V, containing different amounts of putative BvgA binding sites (a); the radiolabelled PCR frag-
ments were incubated with 150 ng (lane 2), 300 ng (lanes 3 and 8), 400 ng (lanes 4 and 9), 500 ng (lanes 5, 10, 13, 17 and 21), 
600 ng (lane 22), 700 ng (lanes 6, 11, 14, 18 and 23) and 800 ng (lanes 15, 19 and 24) of in vitro phosphorylated BvgABH. No pro-
tein was added in lane 1 (DNA probe I), lane 7 (DNA probe II), lane 12 (DNA probe III), lane 16 (DNA probe IV) and lane 20 
(DNA probe V). The reaction mixtures were run on a non-denaturating 4% polyacrylamide gel. F, free DNA probes; C, DNA-
protein complexes.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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sion vector and transferred to the B. holmesii wild type and
the bvgAS mutant strain. GFP expression directed from the
different constructs was used as a measure for promoter
activity. GFP expression was strong in the B. holmesii wild
type strain harbouring construct pMMB208-fhaP-gfp0
containing the entire fhaB  upstream region, while very
low amounts of GFP were detected in the bvgAS mutant
harbouring the same plasmid (Fig. 8, compare lanes 1 and
2). These data confirm the BvgAS mediated regulation of
fhaB expression which was already observed on the tran-
scriptional level (Fig. 3). Moreover, corroborating the in
vitro data, GFP expression was virtually absent in strains B.
holmesii  G7702 (pMMB208-fhaP-gfp4) and B. holmesii
G7702 (pMMB208-fhaP-gfp6) whose gfp expression plas-
mids contained only site BS4 or did not contain a BS site
at all (Fig. 8, lanes 5 and 6). In agreement with the results
of the DNA binding experiments a dramatic increase in
GFP expression could be noted when the fhaB upstream
region in the gfp expression plasmids comprised BS3 or
BS2 and BS3 in addition to BS4 (Fig. 8, lanes 4 and 3). The
virtually identical GFP expression directed from the
pMMB208-fhaP-gfp3  (containing BS3 and BS4) and
pMMB208-fhaP-gfp2  (containing BS2 to BS4) plasmids
was surprising since the EMSA studies reported above
revealed a relatively weak binding of BvgABH-P to a pro-
moter fragment containing BS3 and BS4, while binding to
a fragment comprising BS2 to BS4 was very efficient sug-
gesting a prominent role of BS2 for transcriptional activa-
tion. Since BS3 is fairly similar to the consensus BvgABP
binding motif and is located at the appropriate position to
allow the interaction between BvgABH and the C-terminal
domain of the α subunit of RNA polymerase, BvgABH
binding to BS3 facilitated by DNA topology effects might
be sufficient to fully activate the plasmid-borne fhaB pro-
moter in pMMB208-fhaP-gfp3. In the presence of the full
length fhaB promoter cooperative protein interactions are
likely be involved in the binding of BvgABH to the BS2/BS3
region.
To investigate whether the fhaB promoter of B. holmesii is
also recognized by the BvgA protein of B. pertussis, the
pMMB208-fhaP-gfp0 plasmid containing the entire pro-
moter region of the B. holmesii fhaB gene fused to GFP was
introduced into the B. pertussis strains Tohama I (TI) and
BP359. Strong GFP expression was observed by immuno-
blot analysis in the wildtype strain TI (pMMB208-fhaP-
gfp0), while expression of the reporter gene was hardly
detectable in the bvgAS mutant BP359 (pMMB208-fhaP-
gfp0) (data not shown). Interestingly, primer extension
analysis performed with RNA extracted from TI
(pMMB208-fhaP-gfp0) and BP359 (pMMB208-fhaP-gfp0)
using a gfp-specific oligonucleotide demonstrated that in
the wild type strain transcription of gfp starts at two sites,
which, however, are identical to the start sites of tran-
scripts P1 and P3 synthesized from constitutive (P1) and
bvg-dependent (P3) dependent promoters in B. holmesii.
Moreover, as observed in B. holmesii, in B. pertussis the pro-
moter directing the synthesis of transcript P3 is not tran-
scribed anymore when the BvgAS system is inactivated
(data not shown). These data suggest that the activation
mechanism of the fhaB promoter of B. holmesii by the
BvgA proteins of B. holmesii and B. pertussis is remarkably
similar. This is surprising since it was recently shown that
the BvgA protein of B. holmesii does not bind to and can-
not activate the fhaB promoter of B. pertussis, although in
particular in its C-terminal output domain it is highly
related to the BvgA protein of B. pertussis [27,36].
Immunoblot analysis of protein lysates of B. holmesii strains with a polyclonal anti-GFP antiserum Figure 8
Immunoblot analysis of protein lysates of B. holmesii strains with a polyclonal anti-GFP antiserum. B. holmesii 
G7702 (pMMB208-fhaP-gfp0; BS1 to BS4) (lane 1), B. holmesii G7702 bvgA (pMMB208-fhaP-gfp0; BS1 to BS4) (lane 2), B. holmesii 
G7702 (pMMB208-fhaP-gfp2; BS2 to BS4) (lane 3), B. holmesii G7702 (pMMB208-fhaP-gfp3; BS3 and BS4) (lane 4), B. holmesii 
G7702 (pMMB208-fhaP-gfp4; BS4) (lane 5), B. holmesii G7702 (pMMB208-fhaP-gfp6; no BS) (lane 6). Lysates of E. coli (pSK-fhaP-
gfp0) expressing GFP under control of the pSK lac promoter (lane 7) and of E. coli (pMMB208-fhaP-gfp0) (lane 9) were analysed 
as positive and negative control, respectively. BH-WT, B. holmesii wild type; BH-bvgA, B. holmesii bvgA mutant.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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Conclusion
Little was known so far about the virulence mechanisms
of B. holmesii which can cause pertussis-like disease in
humans and within the genus Bordetella was thought to be
most closely related to B. pertussis. Previous attempts to
identify possible virulence factors related to those of the
etiological agent of whooping cough and of the other
well-characterized Bordetellae were not successful. Here
we describe the identification of a B. holmesii factor related
to the major adhesin of the other pathogenic Bordetellae,
the filamentous hemagglutinin FHA. This adds to our pre-
vious report on the identification of a two-component
system in B. holmesii orthologous to the BvgAS two-com-
ponent system of B. pertussis which in the other patho-
genic Bordetellae is the master regulator of virulence gene
expression and directly controls the expression of FHA.
We show that also in B. holmesii the expression of FHA is
regulated by the BvgAS system and that the activation
mechanism of the fhaB promoter in B. holmesii resembles
that in B. pertussis. These data strongly suggest that basic
virulence mechanisms of B. holmesii and of the other path-
ogenic Bordetellae are related. Furthermore the present
study provides further evidence that B. holmesii may be
more closely related to the bird pathogen B. avium than to
B. pertussis indicating that in the genus Bordetella in differ-
ent phylogenetic lineages independent strains repeatedly
evolved towards being human pathogens.
Methods
Bacterial strains and growth conditions
Bacterial strains used in this study are listed in Table 2. B.
holmesii strains, B. pertussis strains and B. bronchiseptica
strains were grown on Bordet-Gengou (BG) agar plates
supplemented with 20% horse blood [27]. When
required, antibiotics were added to the following final
concentrations: streptomycin, 100 µg ml-1; spectinomy-
cin, 100 µg ml-1; kanamycin, 50 µg ml-1; gentamycin, 15
µg ml-1; ampicillin, 100 µg ml-1 and chloramphenicol, 20
µg ml-1. Bacterial conjugations were performed as
described previously [37], using Escherichia coli SM10 as
the donor strain [38]. Protein lysates were prepared from
bacteria grown on BG agar plates for 48 h at 37°C which
were suspended in saline at a cell density of 1.4 × 108 c.f.u.
ml-1.
General techniques
DNA manipulation, cloning procedures and acrylamide
gel electrophoresis were carried out according to standard
procedures. PCR amplifications were performed with a
model T3 thermocycler (Biometra) using Pfu polymerase
(Promega) or Taq polymerase (Qbiogene Inc.). Oligonu-
cleotides used in this study are listed in Table 3. All cloned
PCR products were subjected to automated sequencing to
ensure proper amplification. Immunoblot analysis was
performed using a semidry blotting procedure as
described previously [39]. Green fluorescent protein
(GFP) was detected using rabbit GFP antiserum (Invitro-
gen).
Characterization of the fhaB locus of B. holmesii
Chromosomal DNA of B. holmesii G7702 was used as tem-
plate for PCR reactions. Primers for PCR reactions were
deduced from conserved DNA regions of the fhaB gene of
B. pertussis and B. avium. Primer pair Fha1F/Fha1R was
deduced from the 5'-end of the fhaB gene (Fha1F: base
pair 514 to 536 in fhaB of B. pertussis; base pair 493 to 515
in fhaB of B. avium; Fha1R: base pair 923 to 944 in fhaB of
B. pertussis; base pair 902 to 923 in fhaB of B. avium).
Primer pair Fha2F/Fha2R was deduced from the 3'-end of
the fhaB gene (Fha2F: base pair 10420 to 10445 in fhaB of
B. pertussis; base pair 7573 to 7598 in fhaB of B. avium;
Fha2R: base pair 10738 to 10757 in fhaB of B. pertussis;
base pair 7877 to 7896 in fhaB of B. avium). Using primer
pairs Fha1F/Fha1R and Fha2F/Fha2R, two fragments of
the expected length (340 bp and 440 bp) could be ampli-
fied from chromosomal DNA of B. holmesii G7702. The
PCR products were sequenced and the sequence analysis
demonstrated that the DNA fragments encoded part of the
fhaB homologue of B. holmesii. The entire fhaB gene of B.
holmesii was sequenced by a genome walking approach
using the Universal Genome Walker Kit (Clontech Inc.).
Construction of B. holmesii and B. pertussis strains 
containing a plasmid with a fusion of the fhaB promoter 
region of B. holmesii to a gfp reporter gene
A 277 bp DNA fragment containing the entire promoter
region of the fhaB gene was PCR amplified from genomic
DNA of B. holmesii G7702 using the primer pair Fhagfp1/
Fhagfp7, thereby introducing BamHI and XbaI restriction
sites at the 5'- and 3'-terminus, respectively. A DNA frag-
ment containing the promoterless gfp-mut2 gene was
excised with XbaI and HindIII from plasmid pKEN [40].
The 277 bp DNA fragment harbouring the fhaB promoter
(termed fhaP0) and the gfp fragment were cloned together
in plasmid pSK, resulting in plasmid pSK-fhaP-gfp0. The
fhaP-gfp0 fragment was then excised by BamHI- and Hin-
dIII-digestion and was subsequently ligated into plasmid
pMMB208. In the resulting plasmid pMMB208-fhaP-gfp0,
the fusion of the promoter fragment and the gfp gene is
located in the opposite orientation to the plasmid-borne
tac  promoter. pMMB208-fhaP-gfp0  was subsequently
transformed into E. coli SM10 and transferred by conjuga-
tion into various B. holmesii and B. pertussis strains. The
same protocol was applied to generate the following con-
structs, which contain fusions of different fhaB promoter
fragments of B. holmesii G7702 with the gfp reporter gene:
pMMB208-fhaP-gfp2  (fhaP2, 224 bp, amplified with
Fhagfp2/Fhagfp7), pMMB208-fhaP-gfp3 (fhaP3, 168 bp,
amplified with Fhagfp3/Fhagfp7), pMMB208-fhaP-gfp4
(fhaP4, 146 bp, amplified with Fhagfp4/Fhagfp7), andBMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
Page 12 of 14
(page number not for citation purposes)
Table 2: Bacterial strains and plasmids
Bacterial strain or plasmid Relevant feature(s) Reference or source
Strains
B. holmesii
ATCC 51541 clinical isolate [19]
No1 clinical isolate [23]
G8341 clinical isolate [19]
G7702 clinical isolate [19]
G7702 bvgA G7702 with a kanamycin-resistance cassette disrupting the bvgA gene [27]
B. pertussis
Tohama I (TI) wildtype, but rpsL [43]
BP359 derivative of TI, bvgA::Tn5 [43]
E. coli
DH5α strain used for high-efficiency transformation Gibco
SM10 mobilizing strain [38]
Plasmids
PbluescriptSK high copy number cloning vector Stratagene
pMMB208 Broad-host-range expression vector [44]
pKEN2 plasmid containing the promoterless gfp-mut2 gene [40]
pSK-FP pSK carrying a 312 bp PCR fragment of B. holmesii G7702 derived from the upstream 
region of fhaB
This study
pSK-fhaP-gfp0 pSK carrying a fusion between 277 bp of the fhaB promoter region of B. holmesii G7702 
harbouring the putative bindings sites BS1–BS4 and the gfp-mut2 gene
This study
pMMB208-fhaP-gfp0 pMMB208 carrying a fusion between 277 bp of the fhaB promoter region of B. holmesii 
G7702 (BS1–BS4) and the gfp-mut2 gene
This study
pMMB208-fhaP-gfp2 pMMB208 carrying a fusion between 224 bp of the fhaB promoter region of B. holmesii 
G7702 (BS2–BS4) and the gfp-mut2 gene
This study
pMMB208-fhaP-gfp3 pMMB208 carrying a fusion between 168 bp of the fhaB promoter region of B. holmesii 
G7702 (BS3–BS4) and the gfp-mut2 gene
This study
pMMB208-fhaP-gfp4 pMMB208 carrying a fusion between 146 bp of the fhaB promoter region of B. holmesii 
G7702 (BS4) and the gfp-mut2 gene
This study
pMMB208-fhaP-gfp6 pMMB208 carrying a fusion between 111 bp of the fhaB promoter region of B. holmesii 
G7702 and the gfp-mut2 gene
This study
Table 3: Oligonucleotides used in this study
Oligonucleotide Sequence (5'-3')* Restriction sites
Fha1F 5'-CTCATCATCGCCAACCCCAACGG -3' -
Fha1R 5'-AGCTGGCGCACGCCCAGGCCTG -3' -
Fha2F 5'-CCCAAGCCCAAGCCCAAGCCCAAGGCC -3' -
Fha2R 5'-ATAGAAGACCCGGTAGTTCT -3' -
FhaBamHI 5'-CCTCGGAGGATCCCCTCCATCGA -3' BamHI
FhaHindIII 5'-TACTTTGCTGAAGCTTAAACGATAG -3' HindIII
Fhagfp1 5'-CCTCGGAGGATCCCCTCCATCGA -3' BamHI
Fhagfp2 5'-ACAACGAGAGGATCCGCAGCAA -3' BamHI
Fhagfp3 5'-CAAAAGGGGATCCACGGGGCAA -3' BamHI
Fhagfp4 5'-AGGGTGCGAGGATCCTGACACA -3' BamHI
Fhagfp6 5'-AAGTGTTGGGATCCGTAGTGTCT -3' BamHI
Fhagfp7 5'-AACGATCTAGATCCGCGCTGCCC -3' XbaI
FhaGR1 5'-GACTATCCTGACACATTGAGGAG -3' -
FhaGR2 5'-CTACATGTAAGTAGGGCCCTGTG -3' -
Gfp1 5'-CAAGAATTGGGACAACTCCAGT -3' -
* Restriction sites introduced for cloning purposes are underlined.BMC Microbiology 2007, 7:100 http://www.biomedcentral.com/1471-2180/7/100
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pMMB208-fhaP-gfp6  (fhaP6, 111 bp, amplified with
Fhagfp6/Fhagfp7).
Primer extension experiments
Total RNA was prepared from bacteria grown on BG agar
plates for 48 h at 37°C. Primer extension experiments
were carried out essentially as described previously [27]
with the primer oligonucleotide Gfp1 (Table 2). Sequenc-
ing reaction mixtures, with plasmid pSK-fhaP-gfp0 as tem-
plate DNA and the appropriate oligonucleotide primer,
were analysed on 6% urea-polyacrylamide gels and used
as standards for determination of the transcription initia-
tion sites.
Gel retardation experiments
A 277 bp DNA fragment (probe I) containing part of the
fhaB upstream region was PCR amplified from genomic
DNA of B. holmesii G7702 using primer pair Fhagfp1/
Fhagfp7. The PCR fragment was 5'-end labelled with [γ-
32P]-ATP using T4 polynucleotide kinase (MBI) and puri-
fied using the QIAquick Nucleotide Removal Kit (Qiagen
Inc.). The His6-BvgABH protein described previously [27]
was diluted in 1 × dilution buffer (2 mM MgCl2, 50 mM
KCl, 0.1% Igepal CA 630, 10 mM DTT) and was phospho-
rylated by incubation with 50 mM acetyl phosphate
(Sigma Inc.) for 20 min at room temperature. Increasing
amounts of the protein were added to approximately
15,000 cpm of the labelled DNA probe in 20 µl of 1 ×
binding buffer (10 mM Tris/HCl, pH 8, 10 mM KCl, 5 mM
EDTA, 1 mM DTT, 10% glycerol, v/v). The samples were
incubated for 20 min at room temperature and were then
loaded onto a non-denaturing 4% polyacrylamide gel.
Gels were run for 2.5 h at 150 V and subsequently the
dried gels were autoradiographed. The same procedure
was applied using the following DNA probes, which were
amplified from the fhaB upstream region of B. holmesii
G7702: probe II (224 bp, amplified by Fhagfp2/Fhagfp7),
probe III (163 bp, amplified by FhaGR1/Fhagfp7), probe
IV (135 bp, amplified by FhaGR2/Fhagfp7) and probe V
(111 bp, amplified by Fhagfp6/Fhagfp7).
DNase I footprinting
DNase I footprint experiments were performed essentially
as described previously [41]. A 312 bp DNA fragment con-
taining part of the upstream region of the fhaB gene was
PCR amplified from chromosomal DNA of B. holmesii
G7702 using primer pair FhaBamHI/FhaHindIII, thereby
introducing BamHI and HindIII restriction sites at the 5'-
and 3'-terminus, respectively. The purified fhaB upstream
fragment was cloned into plasmid pSK. The resulting plas-
mid pSK-FP was digested with BamHI and 5'-end labelled
with [γ-32P]-ATP using T4 polynucleotide kinase. The
labelled promoter fragment was excised from the plasmid
by HindIII digestion, purified by gel electrophoresis and
eluted in 4 ml elution buffer (10 mM Tris/HCl, pH 8, 1
mM EDTA, 300 mM sodium acetate, 0.2% SDS). The
eluted probe was then extracted with phenol/chloroform
(1:1, v/v) and ethanol precipitated. Binding reaction mix-
tures contained various concentrations of BvgABH protein
and approximately 100,000 cpm of labelled DNA probe
in 50 µl of 1 × binding buffer (10 mM Tris/HCl, pH 8, 2
mM MgCl2, 0.1 mM CaCl2, 1 mM DTT, 10% glycerol, v/
v). The samples were incubated 20 min at room tempera-
ture and then the nucleolytic reactions were initiated by
the addition of 1 U DNase I in 1 × binding buffer. After 1
min digestions were terminated by the addition of 140 µl
stop buffer (192 mM sodium acetate, 0.14% SDS, 62 µg
ml-1 yeast tRNA). The samples were extracted with phe-
nol/chloroform (1:1, v/v), ethanol precipitated and run
on a 6% polyacrylamide-urea sequencing gel. A G+A
sequencing reaction was also conducted in parallel with
the labelled DNA probe and subjected to electrophoresis
on the same gel [42].
Accession Number
The DNA sequence reported in this manuscript can be
retrieved by the accession number [EMBL:AM491633].
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